StockWatch
·

Park Medi World Ltd Q2 FY27 Results

PARKHOSPSQ2 FY27 Results
Filing
Result:Weak· Market: Flat#Margin squeeze#Cost led#Broad based
MetricValue (₹ Cr)vs Q1 FY27
Revenue511.027.4%
Total Income520.657.7%
Expenditure444.2417.4%
PBT76.4127.3%
Net Profit54.4638.5%
OPM19.91%6.60pp
NPM10.46%7.87pp
EPS1.2638.5%
View full financials

Revenue grew a healthy 24.6% YoY but adjusted net profit fell 30.8% YoY on broad-based cost growth (materials, staff, other expenses, depreciation all outpacing revenue) tied to newly consolidated Rudrapur capacity running ahead of its revenue contribution, with no one-off items to explain the miss.

Q2 FY-2027 RESULTS · PARKHOSPS

Park Medi World Q2: consolidated PAT down 31% YoY on margin squeeze, revenue up 25%

PAT -30.8% YoY · revenue +24.6% · margins compressing

13 Nov 2026 · 3 min read
Revenue

₹511.03 Cr

+24.6% YoY

PAT (consolidated)

₹54.46 Cr

-30.8% YoY

Net margin

10.46%

EPS

₹1.26

On a consolidated basis — the primary basis here, since the standalone entity is just the listed holding company — Park Medi World's Q2 FY27 revenue from operations grew 24.6% YoY to ₹511.0 Cr (+7.4% QoQ from ₹475.7 Cr), but net profit fell 30.8% YoY to ₹54.5 Cr (₹52.2 Cr to owners of the parent, ₹2.3 Cr to non-controlling interests), down 38.5% QoQ from ₹88.6 Cr in Q1 FY27. There were no exceptional items in either the current or comparative periods, so this is a genuine operating-margin story, not an accounting one.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹511.03 Cr+7.4%—
Expenses₹444.24 Cr+17.4%—
PAT₹54.46 Cr-38.5%-30.8%
Net margin10.46%-7.9pp—
EPS₹1.26-38.5%—

No year-ago quarter on record — YoY cells may be blank.

Net profit margin compressed to 10.5% from 18.8% a year ago and 18.3% last quarter; operating margin (PBT plus depreciation and finance costs, on total income) fell to roughly 21.4% from ~28.9% YoY and ~27.7% QoQ. The squeeze is broad-based rather than one line: cost of materials/services consumed rose 64.2% YoY to ₹116.4 Cr, employee benefit expenses rose 29.5% YoY to ₹100.2 Cr, other expenses rose 36.7% YoY to ₹122.5 Cr and depreciation rose 40.2% YoY to ₹20.9 Cr — all outpacing 24.6% revenue growth, consistent with newly consolidated capacity (V3 Healthcare's 330-bed Rudrapur hospital, acquired and launched August 2, 2026) carrying cost ahead of its revenue contribution.

₹
206.09229.36252.62275.89299.1624308-1009-0109-2410-1911-1111-13Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹243, up 0.7% over the past month of trading.

₹ Cr
033.0766.1599.2252.85Q3 FY26rev ₹410 Cr76.78Q4 FY26rev ₹460 Cr88.59Q1 FY27rev ₹476 Cr54.46Q2 FY27rev ₹511 Cr
Quarterly consolidated PAT, ₹ Crore
What management guided (1 FY-2027 call)
FY'27: Revenue ₹2,080 Cr (24% YoY), EBITDA ₹530 Cr (26-27% margin), PAT ₹360 Cr. Capacity to reach 4,740 beds by FY'27 end, 5,740 beds by FY'28. CGHS rate benefit 7-7.5% (Oct 2025 hike); payor mix to shift to 70:30 (government:private/TPA) over 12-18 months.

— This quarter: missed

Management's FY27 guidance from the August concall called for ₹2,080 Cr revenue, 26-27% EBITDA margin and ₹360 Cr PAT. H1 FY27 revenue of ₹986.7 Cr is 47.4% of that full-year target — broadly on track for a second-half-weighted year — but H1 PAT of ₹143.0 Cr is only 39.7% of the ₹360 Cr goal, and H1 EBITDA margin of ~24.8% already trails the guided band before this quarter's sharper 21.4% print; profitability guidance looks under pressure even as the topline tracks. No analyst previews or consensus estimates for this specific quarter turned up in search — the result was board-approved and announced the same day, November 13, 2026 — so the print cannot be benchmarked against street expectations, and management has issued no press release beyond the regulatory intimation.

  • W1

    H2 FY27 margin recovery toward the guided 26-27% EBITDA band, from ~21.4% this quarter

  • W2

    PAT pace: H1 FY27 PAT of ₹143.0 Cr needs ~₹217 Cr in H2 to hit the ₹360 Cr FY27 guidance

  • W3

    Integration/ramp of newly added capacity (330-bed Rudrapur, 550-bed Prayagraj PPP, 300-bed Kanpur from April 2027, Mehar Mediserve) toward the 4,740-bed FY27 target

Informational and educational content only. Not investment advice.